- Global Pharma News & Resources

2019 Growth Factors (Blood & Tissue) - Worldwide Market Analysis & Forecast (2016-2024) with 101 Key & Niche Player Profiles -

The "Growth Factors (Blood and Tissue) - Market Analysis, Trends, and Forecasts" report has been added to's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following growth factor Types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors.

The report profiles 101 companies including many key and niche players such as:

  • Amgen, Inc.
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Biocon Ltd.
  • Biogen, Inc.
  • BioMimetic Therapeutics LLC
  • Biopharm GmbH
  • Bolder BioTechnology, Inc.
  • F. Hoffmann-La Roche AG
  • Chugai Pharmaceutical Co. Ltd.
  • Genentech, Inc.
  • FibroGen, Inc.
  • Johnson & Johnson
  • Janssen Biotech, Inc.
  • Lonza Group
  • Merck Serono
  • PeproTech, Inc.
  • Reliance GeneMedix Plc
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Scil Proteins GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.

Topics Covered

1. Market Overview

  • Burgeoning Global Population Offers Significant Growth Opportunities
  • Aging Global Population: Need for New Effective Drugs
  • Increasing Healthcare Spending in Emerging Markets: Opportunities in Store
  • Biologics: Rapidly Gaining Ground
  • Erythropoietin (EPO) Market: An Insight
  • Anemia in CKD and Cancer Patients: Opportunity for EPO Therapy
  • Expanding Pool of ESRD and CKD Patients Triggers Sustained Opportunities
  • Rising Tide of Lifestyle Diseases
  • The Grim Reality Fueling Growth in Renal Diseases
  • Comparison of Erythropoietin-Based Drugs in the US and European Union
  • Safety & Efficacy Issues Concerning ESAs
  • Serum Half-Life: A Key Attribute Differentiating ESAs
  • Patent Expiries of Major Interferon Drugs
  • Colony Stimulating Factors (CSFs) Market in Myeloma Patients
  • Interferon-based Drugs for HCV Treatment: An Insight
  • Patent Expiries Fuel Competition and Sales

2. Growth Factors

3. Product Innovations/Approvals/Introductions

4. Recent Industry Activity

5. Focus on Select Players

6. Global Market Perspective

Total Companies Profiled: 101 (including Divisions/Subsidiaries 116)

  • The United States (32)
  • Canada (1)
  • Japan (9)
  • Europe (35)
    • France (2)
    • Germany (14)
    • The United Kingdom (5)
    • Rest of Europe (14)
  • Asia-Pacific (Excluding Japan) (36)
  • Middle East (2)
  • Latin America (1)

For more information about this report visit

View source version on

Editor Details

Last Updated: 16-Jan-2019